Drug Trial Radar · NCT01831427
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Feb 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
74
Actual
Start
Mar 28, 2013
Primary completion
Jan 5, 2015
Study completion Feb 6, 2015
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Apr 15, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are as follows: * To assess the safety and tolerability of escalating single and multiple doses of GS-5745 (andecaliximab) in participants with moderate to severe ulcerative colitis (UC) as assessed by adverse events (AEs) and laboratory abnormalities * To assess the pharmacokinetics (PK) of GS-5745 (andecaliximab) in participants with moderate to severe UC.
Conditions
- Ulcerative Colitis
Interventions
AndecaliximabDrug
Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection
Placebo to match AndecaliximabDrug
Placebo to match andecaliximab administered by IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events (TEAEs) (SAD/MAD)Time frame: SAD Cohorts: First dose date (Day 1) plus 30 days, MAD/Adaptive MAD Cohort: First dose date up to last dose date (Maximum: Day 29) plus 30 days
- Pharmacokinetic (PK) Parameter: Cmax (SAD)Time frame: Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43
- PK Parameter: Cmax (MAD)Time frame: MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Days 1 and 29, Predose on Days 8 and 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Days 1, and 29, Predose on Days 8 and 36
- PK Parameter: Ctau (MAD)Time frame: MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Day 29; Predose on Day 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Day 29; Predose on Day 36
- PK Parameter: AUCinf (SAD)Time frame: Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43
- PK Parameter: AUCtau (MAD)Time frame: MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Days 1 and 29; Predose on Days 8 and 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Days 1, and 29; Predose on Days 8 and 36
- PK Parameter: AUClast (SAD)Time frame: Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43
Locations
16 sites in 7 countries. Site status is shown where the registry gives one.
Delta Research Partners LLC
Monroe, Louisiana
Walter Reed National Military Medical Center
Bethesda, Maryland
Clinical Research Institute of Michigan
Chesterfield Township, MI 48047, Michigan
Ehrhardt Clinical Research, LLC
Belton, Missouri
Duke University Medical Center
Durham, North Carolina
Community Research
Cincinnati, Ohio
UZ Leuven
Leuven, Belgium
GIRI
Vancouver, British Columbia, Canada
LHSC University Campus
London, Ontario, Canada
Drug Research Centre
Balatonfüred, Hungary
Clinical Pharma Center of Kenezy Gyula Korhaz Rendelointezet
Debrecen, Hajdú-Bihar, Hungary
Semmelweis Egyetem Altalanos Orvostudomanyi Kar
Budapest, Pest County, Hungary
Republican Clinical Hospital
Chisinau, Moldova
Academic Medical Center
Amsterdam, Netherlands
Academisch Ziekenhuis Maastricht
Maastricht, Netherlands
Institute of Pulmonology "Marius Nasta"
Bucharest, Romania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.